TNFRSF9 and neoplasm: CD3 bispecific T cell engagers (TCE) can directly trigger Signal 1 and combining them with the anti-CD137 agonist as Signal 2 can overcome resistance to bispecific TCE treatment in T cell-cold solid tumors in preclinical animal tumor models (60), as conceptually illustrated in Figure 3B.